Let's Get Started

Biotech

Guess Who Picked Audentes Therapeutics Inc. (NASDAQ:BOLD) Shares

Guess Who Picked Audentes Therapeutics Inc. (NASDAQ:BOLD) Shares

Apr 26, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Audentes Therapeutics Inc. (NASDAQ:BOLD) reported that Flynn James E  has picked up 1,214,423 of common stock as of 2017-04-26.

The acquisition brings the aggregate amount owned by Flynn James E to a total of 1,214,423 representing less than 4.38% stake in the company.

For those not familiar with the company, Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company’s subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.

A glance at Audentes Therapeutics Inc. (NASDAQ:BOLD)’s key stats reveals a current market capitalization of 409.36 Million based on 26.93 Million shares outstanding and a price at last close of $14.98 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2016-07-25, Woiwode picked up 219 at a purchase price of $15.00. This brings their total holding to 11,308 as of the date of the filing.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Audentes Therapeutics Inc. (NASDAQ:BOLD) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more
Here’s Who Picked Edge Therapeutics Inc. (NASDAQ:EDGE) Shares

Here’s Who Picked Edge Therapeutics Inc. (NASDAQ:EDGE) Shares

Apr 25, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Edge Therapeutics Inc. (NASDAQ:EDGE) reported that Satter Muneer A. has picked up 1,800,000 of common stock as of 2017-04-25.

The acquisition brings the aggregate amount owned by Satter Muneer A. to a total of 1,800,000 representing less than 5.8% stake in the company.

For those not familiar with the company, Edge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions. The Company’s product candidates utilize its programmable, biodegradable polymer-based development platform (the Precisa Platform), a delivery mechanism that seeks to enable targeted and sustained drug exposure and avoid the dose-limiting side effects associated with the current standards of care. The Company’s product candidates include EG-1962 and EG-1964. EG-1962 is a polymer-based microsphere containing nimodipine suspended in a diluent of sodium hyaluronate was developed using its Precisa development platform to improve patient outcomes following aneurysmal subarachnoid hemorrhage (aSAH).

A glance at Edge Therapeutics Inc. (NASDAQ:EDGE)’s key stats reveals a current market capitalization of 341.17 Million based on 30.81 Million shares outstanding and a price at last close of $10.35 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2017-03-06, Loughlin picked up 3,000 at a purchase price of $9.24. This brings their total holding to 6,000 as of the date of the filing.

On the sell side, the most recent transaction saw Leuthner unload 1,500 shares at a sale price of 9.52. This brings their total holding to 245,479.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Edge Therapeutics Inc. (NASDAQ:EDGE) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more
See Who Picked Tocagen Inc. (NASDAQ:TOCA) Shares

See Who Picked Tocagen Inc. (NASDAQ:TOCA) Shares

Apr 25, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Tocagen Inc. (NASDAQ:TOCA)  reported that Foresite Capital Fund Iii, L.p. has picked up 915,000 of common stock as of 2017-04-25.

The acquisition brings the aggregate amount owned by Foresite Capital Fund Iii, L.p. to a total of 915,000              representing less than 4.6% stake in the company.

For those not familiar with the company, Tocagen Inc., (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells. Its lead product candidates are vocimagene amiretrorepvec (Toca 511) and flucytosine extended release (Toca FC). Toca 511 is an investigational injectable retroviral replicating vector (RRV) that encodes a prodrug activator enzyme, cytosine deaminase (CD). Toca FC is an investigational extended-release version of 5-fluorocytosine (5-FC), a prodrug that is inactive as an anti-cancer drug. As of February, 2017, Tocagen has completed enrollment of the Phase II portion with 187 patients.

A glance at Tocagen Inc. (NASDAQ:TOCA)’s key stats reveals a current market capitalization of 238.70 Million based on 18.50 Million shares outstanding and a price at last close of $13.40 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2017-04-19 Das picked up 2,500 at a purchase price of $10.00. This brings their total holding to 2,500 as of the date of the filing.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Tocagen Inc. (NASDAQ:TOCA) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more
Here’s Who Picked Nivalis Therapeutics Inc. (NASDAQ:NVLS) Shares

Here’s Who Picked Nivalis Therapeutics Inc. (NASDAQ:NVLS) Shares

Apr 25, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Nivalis Therapeutics Inc. (NASDAQ:NVLS) reported that Flynn James E has picked up 3,732,414 of common stock as of 2017-04-25.

The acquisition brings the aggregate amount owned by Flynn James E to a total of 3,732,414 representing less than 23.84% stake in the company.

For those not familiar with the company, Nivalis Therapeutics, Inc. is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration. The Company’s S-nitrosoglutathione reductase (GSNOR) inhibitors selectively target GSNOR. Depleted levels of S-nitrosoglutathione (GSNO) have been associated with CF, asthma, inflammatory bowel diseases and certain cardiovascular diseases. The Company’s lead product candidate, cavosonstat (N91115), is a small molecule inhibitor of GSNOR. cavosonstat is a pill that is in two Phase II clinical trials intended to address a defect in CF transmembrane conductance regulator (CFTR), resulting from mutations in the CFTR gene. Its preclinical studies have shown that cavosonstat is a selective and reversible inhibitor of GSNOR.

A glance at Nivalis Therapeutics Inc. (NASDAQ:NVLS)’s key stats reveals a current market capitalization of 30.58 Million based on 15.66 Million shares outstanding and a price at last close of $2.10 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2016-12-02, Carruthers picked up 24,000 at a purchase price of $2.09. This brings their total holding to 24,000 as of the date of the filing.

On the sell side, the most recent transaction saw Rodman unload 6,687 shares at a sale price of 2.27. This brings their total holding to 11,368.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Nivalis Therapeutics Inc. (NASDAQ:NVLS) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more
Agios Pharmaceuticals Inc. (NASDAQ:AGIO) is Attracting Smart Money

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) is Attracting Smart Money

Apr 24, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Agios Pharmaceuticals Inc. (NASDAQ:AGIO) reported that Celgene European Investment Co Llc. has picked up 624,575 of common stock as of 2017-04-24.

The acquisition brings the aggregate amount owned by Celgene European Investment Co Llc. to a total of 624,575 representing less than 1.3% stake in the company.

For those not familiar with the company, Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.

A glance at Agios Pharmaceuticals Inc. (NASDAQ:AGIO)’s key stats reveals a current market capitalization of 2.18 Billion based on 47.27 Million shares outstanding and a price at last close of $47.37 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2017-04-24 Celgene picked up 624,575 at a purchase price of $49.50. This brings their total holding to 1,856,353 as of the date of the filing.

On the sell side, the most recent transaction saw Cantley unload 509 shares at a sale price of $50.92. This brings their total holding to 91,755.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Agios Pharmaceuticals Inc. (NASDAQ:AGIO) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more
Rtw Investments is Buying Ptc Therapeutics Inc. (NASDAQ:PTCT) Shares

Rtw Investments is Buying Ptc Therapeutics Inc. (NASDAQ:PTCT) Shares

Apr 21, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Ptc Therapeutics Inc. (NASDAQ:PTCT) reported that Rtw Investments, Lp. has picked up 1,794,336 of common stock as of 2017-04-21.

The acquisition brings the aggregate amount owned by Rtw Investments, Lp. to a total of 1,794,336 representing less than 5.2% stake in the company.

For those not familiar with the company, PTC Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation. Ataluren is in clinical development for the treatment of Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF). PTC596 is an orally active small molecule that targets tumor stem cell populations by reducing the function, activity and amount of BMI1. RG7916 is an investigational oral therapeutic, which is in two clinical studies: SUNFISH, a trial in childhood onset (Type II/III) spinal muscular atrophy (SMA) patients, and FIREFISH, a trial in infant onset (Type I) SMA patients.

A glance at Ptc Therapeutics Inc. (NASDAQ:PTCT)’s key stats reveals a current market capitalization of 392.91 Million based on 34.56 Million shares outstanding and a price at last close of $11.37 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2016-03-03 Rothera picked up 2,000 at a purchase price of $6.23. This brings their total holding to 5,125 as of the date of the filing.

On the sell side, the most recent transaction saw Almstead unload 78 shares at a sale price of $11.82. This brings their total holding to 2,687.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Ptc Therapeutics Inc. (NASDAQ:PTCT) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more
Guess Who Just Picked Up Tocagen Inc. (NASDAQ:TOCA) Shares

Guess Who Just Picked Up Tocagen Inc. (NASDAQ:TOCA) Shares

Apr 21, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Tocagen Inc. (NASDAQ:TOCA) reported that Biotechnology Value Fund L P has picked up 846,742 of common stock as of 2017-04-21.

The acquisition brings the aggregate amount owned by Biotechnology Value Fund L P to a total of 846,742 representing less than 4.6% stake in the company.

For those not familiar with the company, Tocagen Inc., (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells. Its lead product candidates are vocimagene amiretrorepvec (Toca 511) and flucytosine extended release (Toca FC). Toca 511 is an investigational injectable retroviral replicating vector (RRV) that encodes a prodrug activator enzyme, cytosine deaminase (CD). Toca FC is an investigational extended-release version of 5-fluorocytosine (5-FC), a prodrug that is inactive as an anti-cancer drug. As of February, 2017, Tocagen has completed enrollment of the Phase II portion with 187 patients.

A glance at Tocagen Inc. (NASDAQ:TOCA)’s key stats reveals a current market capitalization of 221.36 Million based on 18.50 Million shares outstanding and a price at last close of $13.27 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2017-04-19 Das picked up 2,500 at a purchase price of $10.00. This brings their total holding to 2,500 as of the date of the filing.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Tocagen Inc. (NASDAQ:TOCA) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more

Feinberg Larry N is Buying Biolase Inc. (NASDAQ:BIOL) Shares

Apr 21, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Biolase Inc. (NASDAQ:BIOL) reported that Feinberg Larry N has picked up 15,472,847 of common stock as of 2017-04-21.

The acquisition brings the aggregate amount owned by Feinberg Larry N to a total of 15,472,847 representing less than 22.58% stake in the company.

For those not familiar with the company, BIOLASE, Inc. (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers. It offers two categories of laser system products: WaterLase (all-tissue) systems and Diode (soft tissue) systems. Its brand, WaterLase, uses a combination of water and laser energy to perform procedures performed using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. It also offers its Diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its Waterlase and Diode systems use disposable laser tips of differing sizes and shapes depending on the procedures being performed.

A glance at Biolase Inc. (NASDAQ:BIOL)’s key stats reveals a current market capitalization of 85.94 Million based on 67.66 Million shares outstanding and a price at last close of $1.29 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2015-10-21 Schuler picked up 33,762 at a purchase price of $0.95. This brings their total holding to 4,213,429 as of the date of the filing.

On the sell side, the most recent transaction saw Mulder unload 5,000 shares at a sale price of $1.25. This brings their total holding to 0.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Biolase Inc. (NASDAQ:BIOL) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more
Here’s Who Just Picked Up Taiwan Fund Inc. (NYSE:TWN) Shares

Here’s Who Just Picked Up Taiwan Fund Inc. (NYSE:TWN) Shares

Apr 21, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Taiwan Fund Inc. (NYSE:TWN) reported that City Of London Investment Group Plc. has picked up 3,481,208 of common stock as of 2017-04-21.

The acquisition brings the aggregate amount owned by City Of London Investment Group Plc. to a total of 3,481,208 representing less than 42.4% stake in the company.

For those not familiar with the company, The Taiwan Fund, Inc. is a diversified, closed-end management investment company. The Fund’s investment objective is to seek long-term capital appreciation through investment primarily in equity securities listed on the Taiwan Stock Exchange (TSE) in the Republic of China (ROC). The Fund invests in various sectors, including biotechnology and medical care; building material and construction; cement; chemical; communications and Internet; computer and peripheral equipment; electric and machinery; electronic parts and components; financial and insurance; foods; oil, gas and electricity; optoelectronic; plastics; semiconductor; shipping and transportation; textiles, and trading and consumers’ goods. The Fund’s investment advisor is JF International Management Inc.

A glance at Taiwan Fund Inc. (NYSE:TWN)’s key stats reveals a current market capitalization of 318.27 Million based on 8.22 Million shares outstanding and a price at last close of $18.27 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2010-09-29 Skinner picked up 4,900 at a purchase price of $16.50. This brings their total holding to 4,900 as of the date of the filing.

On the sell side, the most recent transaction saw Skinner unload 4,900 shares at a sale price of $17.09. This brings their total holding to 0.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Taiwan Fund Inc. (NYSE:TWN) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more